Physician profile
Stephani Schutt
NPI 1386300184
$1,576.96
in general payments reported to CMS, 2019-2025
16 companies · $874 in 2025
The $874 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $44.93 · 2024: $658 · 2025: $874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $375.69 | 2023-2025 | |
| Pfizer INC. | $326.92 | 2024-2025 | |
| Janssen Biotech, INC. | $150.00 | 2024 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $130.00 | 2024 | Voquezna |
| Ucb, INC. | $118.13 | 2024-2025 | Briviact |
| Lilly USA, LLC | $93.58 | 2024-2025 | Kisunla, Emgality, Amyvid |
| Neurelis, INC. | $62.02 | 2024-2025 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $50.05 | 2024-2025 | |
| Axsome Therapeutics, INC. | $48.52 | 2025 | Symbravo |
| Eisai INC. | $45.26 | 2025 | |
| Neurocrine Biosciences, INC. | $44.53 | 2025 | |
| Lundbeck LLC | $31.94 | 2024 | Vyepti |
| Ge Healthcare | $30.04 | 2025 | |
| Livanova USA, INC. | $29.90 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $20.41 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $19.97 | 2025 | Tascenso Odt, Bafiertam |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephani Schutt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.